Immunomodulation by mesenchymal stem cells combats the foreign body response to cell-laden synthetic hydrogels

Biomaterials

Volumn 41, Issue , 2015, Pages 79-88

  Swartzlander, Mark D ^a,b   Blakney, Anna K ^a,e   Amer, Luke D ^a,b   Hankenson, Kurt D ^c   Kyriakides, Themis R ^d   Bryant, Stephanie J ^a,b  

^a University of Colorado   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e University of Washington   (United States)

Author keywords

Foreign body response; Hydrogel; Immunomodulation; Macrophage; Mesenchymal stem cell; Poly(ethylene glycol)

Indexed keywords

ALIPHATIC COMPOUNDS; CELL DEATH; CELL ENGINEERING; CROSSTALK; ETHYLENE GLYCOL; FLOWCHARTING; GENE EXPRESSION; HYDROGELS; IMPLANTS (SURGICAL); MACROPHAGES; MAMMALS; POLYETHYLENE GLYCOLS; POLYOLS; SCAFFOLDS (BIOLOGY); STEM CELLS; TISSUE;

FOREIGN BODY RESPONSE; IMMUNO MODULATIONS; MACROPHAGE ACTIVATION; MESENCHYMAL STEM CELL; OSTEOGENIC DIFFERENTIATION; PRO-INFLAMMATORY CYTOKINES; SCAFFOLDS FOR TISSUE ENGINEERING; TUMOR NECROSIS FACTOR ALPHA;

CELL CULTURE;

INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROGOL; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; HYDROGEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL ENCAPSULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FIBROSIS; FOREIGN BODY REACTION; GENE EXPRESSION; HYDROGEL; IMMUNOMODULATION; IMPLANTATION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PARACRINE SIGNALING; PROTEIN SECRETION; TISSUE ENGINEERING; TISSUE SCAFFOLD; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; IMMOBILIZED CELL; IMMUNOLOGY; INTRACELLULAR SPACE; MESENCHYMAL STROMA CELL; METABOLISM;

MURINAE; MUS;

ANIMALS; CELL DIFFERENTIATION; CELLS, IMMOBILIZED; DINOPROSTONE; FOREIGN-BODY REACTION; HYDROGEL; IMMUNOMODULATION; INTRACELLULAR SPACE; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MALE; MESENCHYMAL STROMAL CELLS; MICE, INBRED C57BL; OSTEOGENESIS; PARACRINE COMMUNICATION;

EID: 84916897728     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.11.020     Document Type: Article

References (50)

1. Langer R., Tirrell D.A. Designing materials for biology and medicine. Nature 2004, 428:487-492.
2. Anderson J.M., Rodriguez A., Chang D.T. Foreign body reaction to biomaterials. Semin Immunol 2008, 20:86-100.
3. Kou J.H., Emmett C., Shen P., Aswani S., Iwamoto T., Vaghefi F., et al. Bioerosion and biocompatibility of poly(d,l-lactic-co-glycolic acid) implants in brain. JControl Release 1997, 43:123-130.
4. Pihlajamaki H., Salminen S., Laitinen O., Tynninen O., Bostman O. Tissue response to polyglycolide, polydioxanone, polylevolactide, and metallic pins in cancellous bone: an experimental study on rabbits. JOrthop Res 2006, 24:1597-1606.
5. Liang Y., Liu W.S., Han B.Q., Yang C.Z., Ma Q., Song F.L., et al. An in situ formed biodegradable hydrogel for reconstruction of the corneal endothelium. Colloids Surf B Biointerfaces 2011, 82:1-7.
6. Suggs L.J., Krishnan R.S., Garcia C.A., Peter S.J., Anderson J.M., Mikos A.G. Invitro and invivo degradation of poly(propylene fumarate-co-ethylene glycol) hydrogels. JBiomed Mater Res 1998, 42:312-320.
7. Kim J., Dadsetan M., Ameenuddin S., Windebank A.J., Yaszemski M.J., Lu L.C. Invivo biodegradation and biocompatibility of PEG/sebacic acid-based hydrogels using a cage implant system. JBiomed Mater Res Part A 2010, 95A:191-197.
8. Swartzlander M.D., Lynn A.D., Blakney A.K., Kyriakides T.R., Bryant S.J. Understanding the host response to cell-laden poly(ethylene glycol)-based hydrogels. Biomaterials 2013, 34:952-964.
9. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
10. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
11. Bartosh T.J., Ylostalo J.H., Mohammadipoor A., Bazhanov N., Coble K., Claypool K., et al. Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc Natl Acad Sci U S A 2010, 107:13724-13729.
12. Ortiz L.A., DuTreil M., Fattman C., Pandey A.C., Torres G., Go K., et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 2007, 104:11002-11007.
13. Nemeth K., Leelahavanichkul A., Yuen P.S.T., Mayer B., Parmelee A., Doi K., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E-2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009, 15:42-49.
14. Choi H., Lee R.H., Bazhanov N., Oh J.Y., Prockop D.J. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood 2011, 118:330-338.
15. Djouad F., Bouffi C., Ghannam S., Noel D., Jorgensen C. Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol 2009, 5:392-399.
16. Carvalho A.B., Quintanilha L.F., Dias J.V., Paredes B.D., Mannheimer E.G., Carvalho F.G., et al. Bone marrow multipotent mesenchymal stromal cells do not reduce fibrosis or improve function in a rat model of severe chronic liver injury. Stem Cells 2008, 26:1307-1314.
17. Blakney A.K., Swartzlander M.D., Bryant S.J. The effects of substrate stiffness on the invitro activation of macrophages and invivo host response to poly(ethylene glycol)-based hydrogels. JBiomed Mater Res Part A 2012, 100:1375-1386.
18. Lynn A.D., Blakney A.K., Kyriakides T.R., Bryant S.J. Temporal progression of the host response to implanted poly(ethylene glycol)-based hydrogels. JBiomed Mater Res Part A 2011, 96:621-631.
19. Lynn A.D., Kyriakides T.R., Bryant S.J. Characterization of the invitro macrophage response and invivo host response to poly(ethylene glycol)-based hydrogels. JBiomed Mater Res Part A 2010, 93A:941-953.
20. Lynn A.D., Bryant S.J. Phenotypic changes in bone marrow-derived murine macrophages cultured on PEG-based hydrogels activated or not by lipopolysaccharide. Acta Biomater 2011, 7:123-132.
21. Jay S.M., Skokos E., Laiwalla F., Krady M.M., Kyriakides T.R. Foreign body giant cell formation is preceded by lamellipodia formation and can be attenuated by inhibition of Rac1 activation. Am J Pathol 2007, 171:632-640.
22. Palsson-McDermott E.M., O'Neill L.A. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 2004, 113:153-162.
23. Cohen H.B., Briggs K.T., Marino J.P., Ravid K., Robson S.C., Mosser D.M. TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses. Blood 2013, 122:1935-1945.
24. English K., Barry F.P., Field-Corbett C.P., Mahon B.P. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 2007, 110:91-100.
25. Prockop D.J., Oh J.Y. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther 2012, 20:14-20.
26. Lee J.W., Fang X., Krasnodembskaya A., Howard J.P., Matthay M.A. Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells 2011, 29:913-919.
27. Vassiliou E., Jing H., Ganea D. Prostaglandin E2 inhibits TNF production in murine bone marrow-derived dendritic cells. Cell Immunol 2003, 223:120-132.
28. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
29. Mills C.D. Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue. Crit Rev Immunol 2001, 21:399-425.
30. Ylostalo J.H., Bartosh T.J., Coble K., Prockop D.J. Human mesenchymal stem/stromal cells cultured as spheroids are self-activated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype. Stem Cells 2012, 30:2283-2296.
31. Maggini J., Mirkin G., Bognanni I., Holmberg J., Piazzon I.M., Nepomnaschy I., et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 2010, 5:e9252.
32. DelaRosa O., Lombardo E. Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential. Mediat Inflamm 2010, 2010:865601.
33. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001, 1:135-145.
34. Shao J., Jung C., Liu C., Sheng H. Prostaglandin E2 stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. JBiol Chem 2005, 280:26565-26572.
35. Martin M., Rehani K., Jope R.S., Michalek S.M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005, 6:777-784.
36. Castellone M.D., Teramoto H., Williams B.O., Druey K.M., Gutkind J.S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310:1504-1510.
37. Deng J., Miller S.A., Wang H.Y., Xia W., Wen Y., Zhou B.P., et al. beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2002, 2:323-334.
38. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., et al. Identification of c-myc as a target of the APC pathway. Science 1998, 281:1509-1512.
39. Zhang S., Li Y., Wu Y., Shi K., Bing L., Hao J. Wnt/beta-catenin signaling pathway upregulates c-myc expression to promote cell proliferation of P19 teratocarcinoma cells. Anat Rec (Hoboken) 2012, 295:2104-2113.
40. Baudino T.A., McKay C., Pendeville-Samain H., Nilsson J.A., Maclean K.H., White E.L., et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002, 16:2530-2543.
41. Haertel E., Werner S., Schafer M. Transcriptional regulation of wound inflammation. Semin Immunol 2014, 26:321-328.
42. Gebler A., Zabel O., Seliger B. The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med 2012, 18:128-134.
43. English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol 2013, 91:19-26.
44. Wagner-Ecker M., Voltz P., Egermann M., Richter W. The collagen component of biological bone graft substitutes promotes ectopic bone formation by human mesenchymal stem cells. Acta Biomater 2013, 9:7298-7307.
45. Chun C., Lim H.J., Hong K.Y., Park K.H., Song S.C. The use of injectable, thermosensitive poly(organophosphazene)-RGD conjugates for the enhancement of mesenchymal stem cell osteogenic differentiation. Biomaterials 2009, 30:6295-6308.
46. da Silva Meirelles L., Chagastelles P.C., Nardi N.B. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. JCell Sci 2006, 119:2204-2213.
47. Meirelles L.D., Caplan A.I., Nardi N.B. In search of the invivo identity of mesenchymal stem cells. Stem Cells 2008, 26:2287-2299.
48. Kalajzic Z., Li H., Wang L.P., Jiang X., Lamothe K., Adams D.J., et al. Use of an alpha-smooth muscle actin GFP reporter to identify an osteoprogenitor population. Bone 2008, 43:501-510.
49. Grcevic D., Pejda S., Matthews B.G., Repic D., Wang L., Li H., et al. Invivo fate mapping identifies mesenchymal progenitor cells. Stem Cells 2012, 30:187-196.
50. Matthews B.G., Grcevic D., Wang L.P., Hagiwara Y., Roguljic H., Joshi P., et al. Analysis of aSMA-labeled progenitor cell commitment identifies notch signaling as an important pathway in fracture healing. JBone Miner Res 2014, 29:1283-1294.